In the whole population, patients with HR+/HER2- advanced breast cancer treated with oral SERDs had significantly improved PFS compared to those treated with standard-of-care ET (HR: 0.75, 95% CI: 0.62-0.91, p = 0.004; I2: 52%, p = 0.08; Fig. 2A). Here, ERBB2 is linked to breast cancer.